Quote Request
Pancreatic Cancer Cell Line Establishment
Alfa Cytology is a leading provider of preclinical services for therapy development in pancreatic cancer (PC). Here, we offer pancreatic cancer cell line establishment and identification services to help researchers and professionals confirm treatment effects or identify other options for follow-up research.
Overview of Pancreatic Cancer
Although relatively uncommon worldwide (2.5% of all forms of cancers), its poor prognosis ranks pancreatic cancer the fourth or fifth in malignancy mortalities. Surgery is still the main treatment for pancreatic cancer, but only 15% to 20% of pancreatic cancer patients can be resected at diagnosis with a poor prognosis after resection. Although the currently available adjuvant therapies appear to provide a survival benefit, they are only moderate, and standard protocols have not been established.
Urgency of Pancreatic Cancer Cell Line Research
Pancreatic cancer stimulates a pro-fibroproliferative response in vivo, thereby expanding the space between tumor cells with reactive non-tumor components (e.g., inflammatory cells and fibroblasts), and reducing the number of viable cancer cells in each macroscopic field of view. Based on this biological nature, some available cell lines are already outdated. Therefore, there is an urgent need to establish and develop more biological resources to facilitate the study of pancreatic cancer.
Fig. 1. Classification of pancreatic ductal adenocarcinoma cell lines according to their characteristics. (Shichi, Y.; et al., 2022)
Our Services
Alfa Cytology is committed to providing our customers with optimal customized services to support basic and translational pancreatic cancer research projects.
Pancreatic Cancer Cell Isolation
The isolation of pure and viable pancreatic cancer cells is a prerequisite for conducting reliable cancer research.
- Rapid isolation of untouched human tumor cells
- Untouched human tumor cells from PDX mouse models
- Untouched mouse tumor cell isolation
Pancreatic Cancer Cell Genetic Engineering
The high heterogeneity of pancreatic cancer results in multiple gene subtypes. Alfa Cytology establishes stable cell lines through genetic engineering to obtain different subtypes of pancreatic cancer cells.
Gene Synthesis
Clone Construction
Virus Packing
Cell Transfection
Antibiotics Screening
Our Technology Platform
Pure, uncontacted cancer cells of different tumor entities can be generated through tumor cell isolation kits and appropriate isolation protocols. Then, specific subpopulations are isolated by positive isolation, enabling high-quality analysis of tumor cell groups.
- Whole exome sequencing (WES)
- Mutation pattern identification
- Flow cytometry
- Gene set enrichment
Our Pancreatic Cancer Cell lines
- Exocrine Tumors
PANC-1, PSN1, AR42J, HaP-T1, HUP-T3, HUP-T4, TGP49, DSL6A/C1, AsPC-1, CFPAC-1
- Endocrine Tumors
CRI-G5, CRI-D11, CRI-D2, TGP52, TGP54, TGP55, RIN-M, RIN-5F
Why Choose Us?
Scientific Experience
Professional team of scientists and more than ten years of experience in pancreatic cancer
Customized Service
Tailored services dedicated to ensuring customer satisfaction
Data Security
Strictly keep confidential the client's project information and experimental data
Quick Reply
Our customer service representatives are available 24 hours a day from Monday to Sunday
Alfa Cytology can establish and characterize a wide range of pancreatic cancer cell lines. Our goal is to establish a living biospecimen repository consisting of pancreatic cancer cell lines to facilitate research on pancreatic cancer. Let us know what you are trying to achieve and our team of experts will contact you within one business day to discuss your needs. Contact us right now!
Reference
- Shichi Y, et al. Epithelial and Mesenchymal Features of Pancreatic Ductal Adenocarcinoma Cell Lines in Two- and Three-Dimensional Cultures. J Pers Med. 2022;12(5):746. Published 2022 May 4. doi:10.3390/jpm12050746
